FIELD: immunology.
SUBSTANCE: group of inventions relates to immunology. A monoclonal antibody specifically binding to thioredoxin-1 (Trx1), or its antigen-binding fragment, including a variable region of the light chain containing CDR1 with SEQ ID NO:1, CDR2 with SEQ ID NO:2, CDR3 with SEQ ID NO:3, and a variable heavy chain region containing CDR1 with SEQ ID NO:4, CDR2 with SEQ ID NO:5, CDR3 with SEQ ID NO:6. Nucleic acid molecules encoding light and heavy chains of a monoclonal antibody or its antigen-binding fragment, a recombinant expression vector, a host cell for obtaining a monoclonal antibody or its antigen-binding fragment, a set and methods for the diagnosis of breast cancer are also proposed.
EFFECT: monoclonal antibody has excellent binding affinity with thioredoxin-1, has high sensitivity and specificity, which significantly improves the accuracy and reliability of breast cancer diagnosis.
25 cl, 22 dwg, 25 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2023 |
|
RU2802944C1 |
MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2791264C2 |
MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
Authors
Dates
2023-02-28—Published
2018-10-12—Filed